ABP 215

• UNSPSC Description:

  ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research[1][2].

• Target Antigen:

  VEGFR

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/abp-215.html

• Solubility:

  10 mM in DMSO

• Smiles:

  [ABP 215]

• References & Citations:

  [1]Neungseon Seo, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018 May/Jun;10(4):678-691. |[2]Whitney Rhodes, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol. 2021 Dec;17(36):5119-5127.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  1438851-35-4